Clinical evaluation of Duraflo® II heparin treated extracorporeal circulation circuits (2nd version) The European working group on heparin coated extracorporeal circulation circuits

European Journal of Cardio-thoracic Surgery

Volumn 11, Issue 4, 1997, Pages 616-623

  Wildevuur, Ch R H ^a,o   Jansen, P G M ^b   Bezemer, P D ^c   Kuik, D J ^c   Eijsman, L ^d   Bruins, P ^d   De Jong, A P ^d   Van Hardevelt, F W J ^d   Biervliet, J D ^d   Hasenkam, J M ^e   Kure, H H ^e   Knudsen, L ^e   Bellaiche, L ^e   Ahlburg, P ^e   Loisance, D Y ^f   Baufreton, C ^f   Le Besnerais, P ^f   Bajan, G ^f   Matta, A ^g   Van Dyck, M ^g   Renotte, M Th ^g   Ponlot Lois, A ^g   Baele, Ph ^g   McGovern, E A ^h   McCarthy, J ^h   McCarthy, A ^h   O'Donnell, A ^h   Fosse, E ⁱ   Moen, O ⁱ   Dregelid, E ⁱ   Brockmeier, V ⁱ   Anderson, C ⁱ   Pomar, J L ^j   Ranucci, M ^k   Conti, D ^k   Cirri, S ^k   Conti, E ^k   Ditta, A ^k   Von Segesser, L K ^l   Tkebuchava, T ^l   Weiss, B M ^l   Turina, M I ^l   Svennevig, J L ^m   Mohr, B ^m   Videm, V ^m   Karlsen, H ^m   Pedersen, T H ^m   Thelin, S ⁿ   Halden E ⁿ   Hagman, L ⁿ   Thorno E ⁿ   Ahlvin, E ⁿ   more..

^a Cardio Pulmonary Center Amsterdam   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f HENRI MONDOR HOSPITAL   (France)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h MATER PRIVATE HOSPITAL   (Ireland)

ⁱ UNIVERSITY OF OSLO   (Norway)

^j UNIVERSITY OF BARCELONA   (Spain)

^k IRCCS POLICLINICO SAN DONATO   (Italy)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m OSLO UNIVERSITY HOSPITAL   (Norway)

ⁿ UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^o European Working Group   (Netherlands)

more..

Author keywords

Cardiac surgery; Clinical outcome; Heparin treated extracorporeal circulation circuits; Multicenter clinical evaluation

Indexed keywords

APROTININ; HEPARIN;

ADULT; AGED; ARTERY CLAMP; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SURGERY; EXTRACORPOREAL CIRCULATION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ADULT; AGED; BLOOD LOSS, SURGICAL; CORONARY ARTERY BYPASS; CORONARY DISEASE; EXTRACORPOREAL CIRCULATION; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SURFACE PROPERTIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 8244238395     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(96)01122-0     Document Type: Article

References (25)

1. Altman D. Practical statistics for medical research. London: Chapman and Hall, 1992:351-8.
2. Andersen LW, Baek L, Degn H, Lehd J, Krasnuk M, Rasmussen JP. Presence of circulating endotoxins during cardiac operations. J Thorac Cardiovasc Surg 1987;93:115-9.
3. Borowiec J, Thelin S, Bagge L, Nilsson L, Venge P, Hansson HE. Heparin coated circuits reduce activation of granulocytes during cardiopulmonary bypass; a clinical study. J Thorac Cardiovasc Surg 1992;104:642-7.
4. Chenoweth DE, Cooper SW, Hugh TE, Steward RW, Blackstone EH, Kirklm JW. Complement activation during cardiopulmonary bypass. Evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304:497-503.
5. Deventer van SJH, Büller HR, Cate ten JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1990;76:2520-6.
6. Fosse E, Moen O, Johnson E et al. Reduced complement and granulocyte activation with heparin coated cardiopulmonary bypass. Ann Thorac Surg 1994;58:472-7.
7. Gu YJ, van Oeveren W, Akkerman C. Boonstra PW, Huyzen RJ, Wildevuur ChRH. Heparin coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:917-22.
8. Gu YJ, van Oeveren W, van der Kamp KWHJ, Akkerman C, Boonstra PW, Wildevuur ChRH. Heparin coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion 1991;6:221-5.
9. Jansen PGM, Velthuis te H, Oudemans-van Straaten HM et al. Perfusion-related factors of endotoxin release during cardiopulmonary bypass. Eur J Cardio-thorac Surg 1994;8:125-9.
10. Jansen PGM. Stepwise reduction in pathophysiologic aspects op cardiopulmonary bypass. Thesis Free University Amsterdam, Netherlands, 1995.
11. Jansen PGM, Baufreton Ch, Le Besnerais P, Loisance DY, Wildevuur ChRH. Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting. Ann Thorac Surg 1996;61:1363-6.
12. Kirklm JK, Westaby S, Blackstone EH, Kirklm JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-57.
13. Marinus JLM. Duraflo®II heparin treated extracorporeal circulation circuits. Anesth Cardiotorac 1995;1:46-57.
14. Mollnes TE, Videm V, Gotze O, Harboe M, Opperman M. Formation of C5a during cardiopulmonary bypass: inhibition by precoating with heparin. Ann Thorac Surg 1991;52:92-7.
15. Nilsson L, Peterson C, Venge P, Borowiec JW, Thelin S. Eosinophil granule proteins in cardiopulmonary bypass with and without heparin coating. Ann Thorac Surg 1995;39:713-6.
16. Pekna M, Hagman L, Halden E, Nilsson UR, Nilsson B, Thelin S. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann Thorac Surg 1994;58:421-4.
17. Ranucci M, Cirri S, Conti D et al. Beneficial effects of Duraflo®II heparin coated circuits on postperfusion lung dysfunction. Ann Thorac Surg 1996;61:76-81.
18. Salama A, Hugo F, Heinrich D et al. Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Eng J Med 1988;318:408-14.
19. Segesser von LK, Wiess BM, Garcia E, Gallino A, Turina M. Reduced blood loss and transfusion requirements with low systemic heparinization: preliminary clinical results in coronary artery revascularization. Eur J Cardiothorac Surg 1990;4:639-43.
20. Segesser von LK, Weiss BM, Pasic M, Garcia E, Turina Ml. Risk and benefit of low systemic heparinization during open heart operations. Ann Thorac Surg 1994;58:391-8.
21. Tabuchi N, Haan de J, Boonstra PW, Oeveren van W. Blood activation in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:828-33.
22. Videm V, Mollnes TE, Garred P, Svennevig JL. Biocompatibility of extracorporeal circulation. In vitro comparison of heparin coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 1991;101:654-60.
23. Videm V, Svennevig JL, Fosse E, Semb G, Østerud A, Mollnes TE. Reduced complement activation with heparin coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992;103:806-13.
24. Wagner WR, Johnson PC, Thompson KA, Marrone GC. Heparin coated cardiopulmonary bypass circuits: Hemostatic alterations and postoperative blood loss. Ann Thorac Surg 1994;58:734-41.
25. Westaby S. Organ dysfunction after cardiopulmonary bypass, a systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Med 1987;13:89-95.